Transgene

Transgene OCF/Debt

The Operating Cash Flow to Debt Ratio of Transgene (TNG.PA) as of Nov 18, 2026 is -230.14 %. In the previous year, Operating Cash Flow to Debt Ratio was -201.53 % — a change of 14.20% (lower).

OCF/Debt

-230.14 %

YoY

14.20%

Last updated:

Operating Cash Flow to Debt Ratio of Transgene is 2024 -230.14 % . Operating Cash Flow to Debt Ratio of Transgene was 2023 -201.53 % . It decreases by 14.20% lower compared to the previous year.

The Transgene OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2017
-83.87 EUR
Jan 1, 2018
-113.28 EUR
Jan 1, 2019
-140.77 EUR
Jan 1, 2020
-560.93 EUR
Jan 1, 2021
-674.01 EUR
Jan 1, 2022
-150.21 EUR
Jan 1, 2023
-201.53 EUR
Jan 1, 2024
-230.14 EUR
The Transgene OCF/Debt history
YEAROCF/DebtYoY
-230.14 %+14.20%
-201.53 %+34.16%
-150.21 %-77.71%
-674.01 %+20.16%
-560.93 %+298.48%
-140.77 %+24.26%
-113.28 %+35.08%
-83.87 %+12.97%
-74.24 %-40.14%
-124.01 %-17.21%
-149.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Operating Cash Flow to Debt Ratio of Transgene is -230.14 % in 2024.

Operating Cash Flow to Debt Ratio of Transgene changed from -201.53 % to -230.14 %, representing a 14.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Transgene since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Transgene

All Key Metrics — Transgene